Cargando…
Virtual Screening in Lead Discovery: A Viewpoint†
Virtual screening (VS) methods have emerged as an adaptive response to massive throughput synthesis and screening technologies. Based on the structure-permeability paradigm, the Lipinski rule of five has become a standard property filtering protocol for VS. Three possible VS scenarios with respect t...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146595/ http://dx.doi.org/10.3390/70100051 |
_version_ | 1783356427844190208 |
---|---|
author | Oprea, Tudor Ionel |
author_facet | Oprea, Tudor Ionel |
author_sort | Oprea, Tudor Ionel |
collection | PubMed |
description | Virtual screening (VS) methods have emerged as an adaptive response to massive throughput synthesis and screening technologies. Based on the structure-permeability paradigm, the Lipinski rule of five has become a standard property filtering protocol for VS. Three possible VS scenarios with respect to optimising binding affinity and pharmacokinetic properties are discussed. The parsimony principle for selecting candidate leads for further optimisation is advocated. |
format | Online Article Text |
id | pubmed-6146595 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-61465952018-11-19 Virtual Screening in Lead Discovery: A Viewpoint† Oprea, Tudor Ionel Molecules Article Virtual screening (VS) methods have emerged as an adaptive response to massive throughput synthesis and screening technologies. Based on the structure-permeability paradigm, the Lipinski rule of five has become a standard property filtering protocol for VS. Three possible VS scenarios with respect to optimising binding affinity and pharmacokinetic properties are discussed. The parsimony principle for selecting candidate leads for further optimisation is advocated. MDPI 2002-01-31 /pmc/articles/PMC6146595/ http://dx.doi.org/10.3390/70100051 Text en © 2002 by Tudor Ionel Oprea (tudor.oprea@astrazeneca.com). Reproduction is permitted for non commercial purposes |
spellingShingle | Article Oprea, Tudor Ionel Virtual Screening in Lead Discovery: A Viewpoint† |
title | Virtual Screening in Lead Discovery: A Viewpoint† |
title_full | Virtual Screening in Lead Discovery: A Viewpoint† |
title_fullStr | Virtual Screening in Lead Discovery: A Viewpoint† |
title_full_unstemmed | Virtual Screening in Lead Discovery: A Viewpoint† |
title_short | Virtual Screening in Lead Discovery: A Viewpoint† |
title_sort | virtual screening in lead discovery: a viewpoint† |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146595/ http://dx.doi.org/10.3390/70100051 |
work_keys_str_mv | AT opreatudorionel virtualscreeninginleaddiscoveryaviewpoint |